US COVID-19 Insights - Trending Developments, Company Announcements and Analysis from the Analysis Team on Fast-Breaking Events - ResearchAndMarkets.com

DUBLIN--()--The "COVID-19 Update: Impact on Molecular Diagnostics, Serology, Critical Care Tests, Vaccines and Telehealth Markets" report has been added to ResearchAndMarkets.com's offering.

The current COVID-19 crisis affecting the United States and the world has caused hundreds of thousands of deaths and countless economic costs. This has brought forth an array of solutions that could contribute to detecting, containing, and possibly treating the disease. The analyst has covered the fields of molecular diagnostics, vaccines, and telehealth for decades. These important industries, already growing in revenues and number of competitors, now find themselves part of the current crisis. This COVID-19 Update provides trending developments, company announcements, and analysis from the analysis team on fast-breaking events in the COVID-19 pandemic.

Early COVID-19 IVD Market Estimates - Moderate Case, Best Case, Worst Case

In preparing market analysis, the analyst normally consults detailed financial information from the major in vitro diagnostics firms to obtain accurate results. In the throes of this crisis, such data are lacking. However, using the many statements that have been issued plus knowledge gleaned from the analyst's databases on flu and other molecular testing.

Molecular Diagnostics

Testing for viruses is normally conducted using RT-PCR, a form of molecular testing. To a lesser degree, antibody tests are used. Both types of testing have been present in the COVID-19 crisis. The report takes a particular interest in molecular diagnostics, the segment in vitro diagnostics directly affected by COVID-19.

Serology Tests

Serology tests are serum-based immunoassays that are inexpensive and run on high-volume analyzers that are very common in hospital and reference labs, in contrast to PCR tests, which tend to be more complex and expensive. These tests look for the presence of host antibodies that a patient may have developed in reaction to the disease, rather than detecting the disease itself. In so doing, serology tests at some point could ascertain whether patients have immunity, though mechanisms of immunity have not been fully explored with COVID-19.

Other IVD Tests

The results of a survey on the US Impact on Hospital and Reference Test Volume have pointed toward other in vitro diagnostic testing that may provide useful COVID-19 insights.

Vaccines, Remote Patient Monitoring, and Other Impacted Markets

COVID-19's influence is being felt across the healthcare spectrum. The report examines the virus' impact on the vaccines market, non-COVID testing, remote patient monitoring/telehealth and lab automation, including:

  • Select Vaccines in Development for COVID-19
  • Selected Automated Molecular Test Instrument Platforms
  • Non-COVID Testing: Magnitude of Pandemic Impact
  • Remote Patient Monitoring: Companies to Watch

Companies include:

  • Abbott
  • AMD Global Telemedicine
  • American Well (Amwell)
  • Becton Dickinson (BD)
  • bioMrieux
  • Bio-Rad
  • BioTelemetry, Inc.
  • Bruker
  • CanSino Biologics
  • Cepheid
  • Doctor on Demand
  • Eko Devices
  • Fluidigm
  • GD (General Devices)
  • GlobalMed
  • Glooko
  • Inovio Pharmaceuticals
  • Masimo
  • MediOrbis
  • Medtronic
  • Meridian Bioscience
  • Moderna
  • Myriad Genetics
  • Natera
  • Qiagen
  • Quidel
  • Rheonix, Inc.
  • Roche
  • SD Biosensor
  • Seegene
  • Teladoc Health
  • Thermo Fisher Scientific
  • Thinklabs
  • Twist Bioscience
  • TytoCare

Key Topics Covered:

CHAPTER ONE: SARS-COV-2 RECENT DEVELOPMENTS

  • BRISK FIRST QUARTER RESULTS AT MOLECULAR DIAGNOSTICS COMPANIES
  • SMALLER, MID-SIZE MDX SEE DOUBLE-DIGIT BOOSTS
  • MOLECULAR LIFE SCIENCE COMPANY REVENUES DOWN
  • MOLECULAR TESTING: A LEARNING CURVE
  • Large Number of Approvals
  • TEST APPROVED BY FDA
  • ANTIBODY TESTING POISED TO GROW
  • Current Serology Tests
  • Creative Solutions for Lab Shortages
  • MOLECULAR DIAGNOSTIC TESTING UP, OVERALL DIAGNOSTICS TESTING TAKING A HIT IN NEW SURVEY
  • Overall US Lab Test Volume
  • Budget and New Purchases
  • Quest Reports Change in Volume
  • REOPENING PLANS
  • Taiwan Case Study
  • Advice on Reopening for the U.S. from CDC
  • SUPPLY ISSUES
  • WHEN WILL SURGERIES - AND RELATED DIAGNOSTIC TESTING - RESUME?
  • CARES ADDS $25 BILLION IN FUNDING
  • BACKGROUND
  • UPTICK IN NON-COVID-19 TEST COMPANY ANNOUNCEMENTS
  • WILL WE SEE FUNDAMENTAL CHANGE IN IVD?
  • EARLY COVID-19 IVD ESTIMATES - MODERATE CASE, BEST CASE, WORST CASE
  • Best Case IVD Market Assumptions
  • Moderate Case IVD Market Assumptions
  • Worst Case IVD Market Assumptions

CHAPTER TWO: COVID-19 MOLECULAR ASSAYS

  • AUTHORIZED TEST FROM TOP-TIER IVD COMPANIES
  • Roche
  • Abbott
  • bioMrieux - R -GENE
  • Bio-Rad
  • Seegene, SD Biosensor
  • Rheonix, Inc.
  • Becton Dickinson
  • Thermo Fisher Scientific
  • Qiagen QIAstat-Dx
  • MOLECULAR POINT OF CARE
  • Abbott - ID NOW
  • Cepheid - Gene Expert
  • bioMrieux - BioFire
  • ALL RT-PCR TESTS ON THE MARKET
  • THREE: COVID-19 SEROLOGY TESTS
  • MAJOR VENDORS LAUNCH ANTIBODY TESTS
  • GOOD NEWS ABOUT NEUTRALIZING ANTIBODIES
  • Investigating Cellular Immune Responses
  • FDA ACTIONS RELATED TO SEROLOGY TESTS
  • Review Focused on Commercial Companies
  • SERUM/WHOLE BLOOD TESTS
  • FINGERSTICK TESTS

CHAPTER FOUR: TESTS TO WATCH: BLOOD GAS, PCT, TROPONIN, D-DIMER, OTHERS

  • RESULTS OF SURVEY - US IMPACT ON HOSPITAL AND REFERENCE TEST VOLUME
  • CRITICAL CARE CHEMISTRIES
  • Blood Gas Testing
  • D-DIMER
  • CARDIAC TROPONIN
  • PCT
  • CRP
  • AKI TESTING
  • FERRITIN
  • HOSPITAL INFECTIONS
  • Cytokine Storms and COVID-19 Weaken Patient Immune System

CHAPTER FIVE: LAB AUTOMATION AND COVID-19

CHAPTER SIX: NON-COVID TESTING DOWN

  • STAFFING TOPS LIST OF CONCERNS
  • RAMPING UP TESTING AS STATES REOPEN

CHAPTER SEVEN: VACCINES AND SARS-COV-2

CHAPTER EIGHT: REMOTE PATIENT MONITORING AND THE COVID-19 CRISIS

  • COMPANIES TO WATCH

For more information about this report visit https://www.researchandmarkets.com/r/89r2ge

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900